Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

The aim of this study was to investigate the early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice. Forty patients with Child-Pugh class A liver function and eastern cooperative oncology group performance statu...

Full description

Bibliographic Details
Main Authors: Yuwa Ando, Tomokazu Kawaoka, Masanari Kosaka, Yuki Shirane, Yusuke Johira, Ryoichi Miura, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yumi Kosaka, Shinsuke Uchikawa, Kenichiro Kodama, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Masami Yamauchi, Wataru Okamoto, Shoichi Takahashi, Michio Imamura, Kazuaki Chayama, Hiroshi Aikata
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
hepatocellular carcinoma
atezolizumab
bevacizumab
immune checkpoint inhibitor
tumor marker
α-fetoprotein
Online Access:https://www.mdpi.com/2072-6694/13/16/3958

Internet

https://www.mdpi.com/2072-6694/13/16/3958

Similar Items